Diacylglycerol lipase alpha (DAGLA) has been identified as a novel autoantibody target in patients with rapid progressive cerebellar ataxia. The autoantibodies were characterised as part of a collaborative study between scientists at EUROIMMUN (Lübeck, Germany), the Hannover Medical School, (Hannover, Germany) and further institutes and clinics. The study was published in April 2024 the journal […]

Two new studies on SARS-CoV-2 vaccine immune responses suggest that the XBB.1.5-containing mRNA vaccines most likely increase protection against COVID-19 caused by currently circulating XBB variants and the emerging BA.2.86 variant in healthy persons and in patients on haemodialysis. The studies build on collaborative work between the Hannover Medical School, Germany and EUROIMMUN and were

EUROIMMUN has been offering test systems for therapeutic drug monitoring (TDM) since 2019. Owing to the cooperation with IDS and their range of TDM products from Theradiag, we were able to significantly expand our portfolio: We are now offering ELISA and ChLIA test systems for the therapeutic monitoring of different biologics and antibodies against them

Our main goal is to offer our customers not only a broad range of assays, but also a flexible choice of automation solutions. Therefore, this year, we have provided proofs of compatibility for a total of 89 indirect immunofluorescence tests (IIFT) with the automated EUROPattern Microscope Live. Now, our fastest microscope can be used on

Anti-TBE Virus ELISA 2.0 (IgG) After EUROIMMUN received the required certificate for its quality management system in accordance with the new European Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) in May of this year, the first newly developed IVD product of risk class B has now also been declared IVDR-compliant and launched